Merck Reports Q3 Earnings Beat Driven by Keytruda and Gardasil Growth
Merck & Co., Inc. (MRK) reported third-quarter financial results that exceeded analyst expectations, characterized by strong revenue growth and an earnings beat. The company's oncology blockbuster, Keytruda, reached $8.60 billion in sales, while the Gardasil vaccine line showed a significant recovery, reaching $1.99 billion. Driven by these performance metrics, Merck raised its 2026 outlook. Additionally, positive clinical developments were noted regarding a melanoma combination therapy being developed in collaboration with Moderna, which has delivered promising Phase 3 trial results.
Topics: clinical trial results earnings report EPS beat guidance increase revenue beat